# Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct02589639` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02589639](<https://clinicaltrials.gov/study/NCT02589639>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02589639

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 269 participants.

## Technical summary

Registry record NCT02589639. Randomized; no masking; primary purpose treatment. Start 2015-10-28 (actual); primary completion 2017-04-18 (actual). Results posted on 2019-03-27.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 269 participants (enrolled count; ClinicalTrials.gov record NCT02589639, source copy `cardio:ctgov-nct02589639-2019-03-27`, retrieved 2026-10-26)
- Started: 2015-10-28 (actual) (ClinicalTrials.gov record NCT02589639, source copy `cardio:ctgov-nct02589639-2019-03-27`, retrieved 2026-10-26)
- Primary completion: 2017-04-18 (actual) (ClinicalTrials.gov record NCT02589639, source copy `cardio:ctgov-nct02589639-2019-03-27`, retrieved 2026-10-26)
- Completion: 2018-01-05 (actual) (ClinicalTrials.gov record NCT02589639, source copy `cardio:ctgov-nct02589639-2019-03-27`, retrieved 2026-10-26)
- Results first posted: 2019-03-27 (ClinicalTrials.gov record NCT02589639, source copy `cardio:ctgov-nct02589639-2019-03-27`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT02589639, source copy `cardio:ctgov-nct02589639-2019-03-27`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02589639-2019-03-27`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of Empagliflozin as add-on to Insulin in Japanese Patients With Type 2 Diabetes Mellitus
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Intervention (Drug): Placebo
- Lead sponsor: Boehringer Ingelheim
- Lead sponsor class: INDUSTRY
- Collaborator: Eli Lilly and Company
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Boehringer Ingelheim (`cardio:boehringer-ingelheim`)
- Registry lists this organization as a collaborator: Eli Lilly and Company (`cardio:eli-lilly`)

## Provenance

Content hash: 9ceb7e7a9732aa45681ccfb35ba464424fde8e75f2a316ddf785b2e90196d957
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
